• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Industry troubled by performance trends in FDA user fee program

Industry troubled by performance trends in FDA user fee program

September 20, 2010 By Ingrid Mezo

It takes 20 percent longer to obtain a final decision on a 510(k) submission than it did in 2002, despite the millions the Food & Drug Administration has collected from medical device makers in so-called "user fees," according to AdvaMed’s Janet Trunzo.

Trunzo, AdvaMed’s executive vice president for technology and regulatory affairs, was one of several industry association speakers who expressed disappointment in the medical device user fee program at a Sept. 14 workshop held to gain stakeholder input on the program.

"Our companies are concerned that the link between performance and fees has broken down," said Medical Imaging and Technology Alliance executive director David Fisher.

"FDA’s medical device program has benefited from significant funding increases in recent years," Trunzo added, noting a 37 percent percent budget increase and a 14 percent rise in staffing levels to FDA’s device program since 2007. "The 2007 re-authorization for the user fee program doubled the industry’s contribution to the agency’s funding."

More

  • Part II: Industry pushes for better guidance

The FDA first gained authority to collect user fees under the 2002 Medical Device User Fee and Modernization Act. Since medical device user fees were reauthorized in 2007 under the Medical Device User Fee Amendments, the federal watchdog agency has met some of its performance goals — for 510(k)s, 180-day and real-time pre-market approval supplements — but has failed to meet others for original and expedited PMAs and their panel track supplements, according to a recent fiscal 2009 performance report to Congress.

But the agency stands behind the user fee program, which must be reauthorized before its September 2012 expiration date. Dr. Jeffrey Shuren, director of the FDA’s Center for Devices and Radiological Health, underscored that "while user fees provide a stable source of funding, [industry money] accounts for less than 20 percent of funding for CDRH activities covered by the user fee program and only roughly 1/12 of the user fee funding provided for the agency’s human drug program."

Industry has been particularly focused on the 510(k) program because FDA is now considering more than 70 changes to the process in response to concerns from healthcare professionals, patient and third-party payer groups. They argue that the program allows devices to enter the market without sufficient evidence of safety and effectiveness. AdvaMed recently released a related analysis to demonstrate that the program works just fine as is, citing the fact that less than 1 percent of 510(k)-cleared devices were involved in Class I recalls since 1998.

Through increased funding from both user fees and higher Congressional appropriations, the FDA now reviews more than 90 percent of 510(k)s within 90 days, compared to 75 percent prior to 2003, Shuren said. "This means nearly 500 more 510(k)s receive a timely review each year than at the pre-user fee performance level."

But the agency’s performance report for 2009 (PDF), which shows that the agency’s 510(k) performance goals were met for fiscal 2008 and 2009 and are on track for 2010, fails to tell "the whole story related to the 510(k) review system," Trunzo said.

Per submission, the average number of review cycles — the times when FDA stops the review clock and asks for additional information — has increased by 36 percent since 2002, she noted.

Companies are also now taking almost three times as long to respond to FDA’s questions when the agency stops the clock to ask for additional information — from an average of 19 days in 2002 to 51 days now, according to Trunzo.

"As a result, the average total time from receipt of the 510(k) at FDA to the decision made by FDA has risen 20 percent since 2002," she said.

Industry: The interactive review process needs work

The FDA has yet to make good on its commitment during the 2007 re-authorization to formalize the interactive review process, according to MITA’s Fisher and Medical Device Manufacturers Assn. president and CEO Mark Leahy.

"We feel like today isn’t that much different than it was four, five, six years ago, and as a result, feel like the agreements that we reached back in 2007 haven’t, ultimately, been met," Fisher said.

Leahy pointed to "more and more examples of where that interactive collaboration and cooperation is falling short, where phone calls aren’t getting returned, emails aren’t being responded to, [resulting in] these dark periods of three to four months."

Such communication problems tend to occur with new reviewers, Leahy acknowledged, and the agency "is doing an extraordinary job trying to provide additional training through their various programs … but these are things that we just need to keep working on … to restore that collaborative partnership environment versus the adversarial, confrontational environment," he said.

In response to some stakeholders’ suggestions that medical device companies fund an even higher share of the FDA’s medical device center budget (on par with the drug industry’s heftier contributions), Leahy underscored the differences between the medical device and drug industries.

While the average market size for a medical device is about $120 million, for a drug it’s about $1 billion, he noted.

And while drugs can enjoy market exclusivity for around a decade, medical devices remain exclusive for a much shorter period, generally a couple of years, Leahy said.

"From venture capitalists’ perspective, if the costs to bring a product to market exceed what they can recoup in sales, guess what? The medical innovation ecosystem collapses as we know it."

Separately, MITA’s Fisher pointed out that device companies will have to begin paying a 2.3 percent device tax in 2013, which will leave "less money available for other things, such as user fees."

Tomorrow: Industry wants faster, more user-friendly guidance

Filed Under: Food & Drug Administration (FDA), Medical Device Manufacturers Assn. (MDMA), News Well Tagged With: AdvaMed, Gift Bans, Industry Council, Medical Imaging & Technology Alliance (MITA)

In case you missed it

  • How Stryker includes users for product design in the digital age
  • DermaSensor wins MedTech Innovator Mid-Stage Companies Pitch Event
  • FDA approves Medtronic’s Onyx Frontier drug-eluting coronary stent
  • Medtronic completes Intersect ENT acquisition
  • Steris rises on Street-beating Q4, sets fiscal 2023 guidance
  • Medtronic must sell Intersect ENT subsidiary to satisfy FTC concerns
  • Abbott partners with Women as One to help more underrepresented clinicians lead trials
  • Lucira Health asks FDA for EUA on molecular at-home COVID/flu test
  • Device commercialization platform AcuityMD raises $31M Series A to fund R&D engineer hiring
  • Abbott announces availability of Xience Skypoint drug-eluting stent in extended sizes
  • GE Healthcare to invest $50M in Pulsenmore to enter homecare segment
  • BD launches automated infectious disease diagnostic platform in the U.S.
  • DarioHealth rises on Street-beating Q1
  • Here’s what’s next for Insulet after the launch of Omnipod 5, CEO change
  • Stryker leaders talk medtech trends at DeviceTalks Boston: ‘If you’re slow, you’re going to lose’
  • Moderna’s new CFO leaves after former employer discloses investigation
  • How technology is changing the operating room

RSS From Medical Design & Outsourcing

  • How Stryker includes users for product design in the digital age
    Medical device developers and manufacturers like Stryker (NYSE:SYK) are changing how they approach design as digital technology becomes more crucial. Four Stryker executives shared how the Kalamazoo, Michigan–based orthopedic device giant is thinking differently about medical product development and how health care providers and patients will ultimately use them. The DeviceTalks Boston panel of Stryker… […]
  • DermaSensor wins MedTech Innovator Mid-Stage Companies Pitch Event
    DermaSensor Inc. — the creator of a handheld, point-and-click device to quickly assess skin lesions for cancer risk — is the winner of the MedTech Innovator Mid-Stage Companies Pitch Event.  The Miami-based mid-stage company beat out 1,000 applicants, more than 20 of which competed on-site May 10–11, 2022 at DeviceTalks Boston. DermaSensor walked away with… […]
  • Steris rises on Street-beating Q4, sets fiscal 2023 guidance
    Steris (NYSE:STE) shares ticked up today on fourth-quarter financial results that came in just ahead of the consensus forecast. The infection prevention technology company — headquartered in Dublin, Ireland, and run operationally out of Mentor, Ohio — posted profits of $52.3 million, or 52¢ per share, on sales of $1.2 billion for the three months… […]
  • Lucira Health asks FDA for EUA on molecular at-home COVID/flu test
    Lucira Health (Nasdaq: LHDX) today said it has asked the FDA for an emergency use authorization (EUA) for its combination COVID-19 and flu test. Emeryville, California–based Lucira said the at-home test would be available with a prescription to test for SARS-CoV-2, Influenza A and Influenza B. The Nucleic Acid Amplification Test (NAAT) platform has a… […]
  • Device commercialization platform AcuityMD raises $31M Series A to fund R&D engineer hiring
    AcuityMD said today it has raised $31 million in Series A funding for its medical device commercialization platform. “With our new funding, we plan to double down on R&D by growing our engineering team from 15 to over 40 over the next year,” AcuityMD co-founder and CEO Michael Monovoukas said in a blog post. “We’ll… […]
  • Rockley Photonics announces $81.5M private placement
    Rockley Photonics (NYSE:RKLY) announced today that it entered into agreements for an $81.5 million private placement. Participating investors agreed to purchase $81.5 million in convertible senior secured notes (due 2026) and warrants to purchase 26.5 million Rockley ordinary shares at an exercise price of $5 per share, subject to certain anti-dilution adjustments. Warrants purchased in… […]
  • Stryker leaders talk medtech trends at DeviceTalks Boston: ‘If you’re slow, you’re going to lose’
    The first day of DeviceTalks Boston closed with a panel of Stryker (NYSE:SYK) executives discussing new tools, technologies and strategies in medtech. Digital VP Tracy Robertson, Digital, Robotics, and Enabling Technologies President Robert Cohen and Surgical Technologies VP of Digital Innovation Siddarth Satish offered their thoughts on industry trends in healthcare and at the Kalamazoo,… […]
  • Medtronic’s VC leader discusses risk, returns, strategy and an ‘ugly truth’
    A panel of medtech investors convened today for DeviceTalks Boston included David Neustaedter, VP of venture capital at Medtronic (NYSE: MDT). He’s spent 14 years in the role, including as director of venture capital at Covidien before Medtronic acquired the company. (Read more in his DeviceTalks speaker bio.) Medtronic has more than $500 million in… […]
  • Here’s where Harvard’s engineering dean sees medtech research going
    Surgical robotics, artificial intelligence, and combatting climate change are but some of the priorities that have Harvard’s engineering school dean excited. Speaking today at DeviceTalks Boston, Frank J. Doyle III described the Harvard John A. Paulson School of Engineering and Applied Sciences as a “well-kept secret” historically. But Harvard engineering is staking out a strong position when it… […]
  • gBETA Medtech accelerator picks its next startups
    The gBETA Medtech virtual accelerator today named the five startups that will participate in the spring program leading up to the June 21 showcase day. The five startups for the spring 2022 cohort are: Mother of Fact: This mobile app for moms with babies offers nutrition tracking, preventative monitoring and daily coaching from licensed dietitians… […]
  • FDA warns of potential toxic risk from Fresenius hemodialysis machines
    The FDA is evaluating the risk of exposure to toxic chemicals from silicone tubing used in Fresenius Medical Care (NYSE: FMS) hemodialysis machines. The investigation concerns three models of Fresenius hemodialysis machines: the 2008T, 2008K2, and 2008K. The chemicals — non-dioxin-like (NDL) polychlorinated biphenyl acids (PCBAs) and NDL polychlorinated biphenyls (PCBs) — are in the… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS